"Balancing Expectations With Actual Realities": Conversations With Clinicians and Scientists in the First Year of a High-Risk Childhood Cancer Precision Medicine Trial
Affiliations
- PMID: 32075154
- DOI: 10.3390/jpm10010009
Abstract
Precision medicine is changing cancer care and placing new demands on oncology professionals. Precision medicine trials for high-risk childhood cancer exemplify these complexities. We assessed clinicians' (n = 39) and scientists' (n = 15) experiences in the first year of the PRecISion Medicine for Children with Cancer (PRISM) trial for children and adolescents with high-risk cancers, through an in-depth semi-structured interview. We thematically analysed participants' responses regarding their professional challenges, and measured oncologists' knowledge of genetics and confidence with somatic and germline molecular test results. Both groups described positive early experiences with PRISM but were cognisant of managing parents' expectations. Key challenges for clinicians included understanding and communicating genomic results, balancing biopsy risks, and drug access. Most oncologists rated 'good' knowledge of genetics, but a minority were 'very confident' in interpreting (25%), explaining (34.4%) and making treatment recommendations (18.8%) based on somatic genetic test results. Challenges for scientists included greater emotional impact of their work and balancing translational outputs with academic productivity. Continued tracking of these challenges across the course of the trial, while assessing the perspectives of a wider range of stakeholders, is critical to drive the ongoing development of a workforce equipped to manage the demands of paediatric precision medicine.
Keywords: delivery of healthcare; genomics; neoplasms; pediatrics; precision medicine.
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Similar articles
- Integrating Next-Generation Sequencing Into Pediatric Oncology Practice: An Assessment of Physician Confidence and Understanding of Clinical GenomicsLM Johnson et al. Cancer 123 (12), 2352-2359. PMID 28192596.Among physicians at a comprehensive pediatric cancer center, confidence in the interpretation, use, and discussion of oncology-based genomic test results appears to be lo …
- Integrating Genomics Into Clinical Oncology: Ethical and Social Challenges From Proponents of Personalized MedicineML McGowan et al. Urol Oncol 32 (2), 187-92. PMID 24445286.These specific concerns are not unique to oncology, or even genomics. However, those most invested in the success of PM view oncologists' responses to these challenges as …
- Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine ConferenceWA Hall et al. Int J Radiat Oncol Biol Phys 101 (2), 274-284. PMID 28964588.Genomically guided radiation therapy is a necessity that must be embraced in the coming years. Incorporating these data into treatment recommendations will provide radiat …
- Oncologists' and Pediatric Oncologists' Perspectives and Challenges for Fertility PreservationC Lampic et al. Acta Obstet Gynecol Scand 98 (5), 598-603. PMID 30714120. - ReviewInternational guidelines recommend that health-care providers initiate discussions about the impact of treatment on fertility with cancer patients of reproductive age, or …
- Precision Medicine in Pediatric OncologySJ Forrest et al. Curr Opin Pediatr 30 (1), 17-24. PMID 29189430. - ReviewThe primary results of the first round of pediatric precision oncology clinical trials will provide us with a greater understanding of the clinical impact of linking tumo …
No hay comentarios:
Publicar un comentario